Maravai LifeSciences Holdings (STU:MAR) ROCE % : -3.32% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Maravai LifeSciences Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -3.32%.

Maravai LifeSciences Holdings ROCE % Historical Data

The historical data trend for Maravai LifeSciences Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings ROCE % Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

4.63

12.92

38.92

29.46

36.50

Maravai LifeSciences Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															1.33	-1.15	-1.64	147.72	-3.32

Maravai LifeSciences Holdings ROCE % Calculation

Maravai LifeSciences Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	608.547	/	( ( (2154.505 - 103.976)	+	(1363.992 - 80.208) )	/ 2 )
	=	608.547	/	( (2050.529	+	1283.784)	/ 2 )
	=	608.547	/	1667.1565
	=	36.50 %

Maravai LifeSciences Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-42.484	/	( ( (1363.992 - 80.208)	+	(1329.07 - 54.3) )	/ 2 )
	=	-42.484	/	( ( 1283.784	+	1274.77 )	/ 2 )
	=	-42.484	/	1279.277
	=	-3.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Maravai LifeSciences Holdings (STU:MAR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Maravai LifeSciences Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings (STU:MAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (STU:MAR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MRVI:USA MRVI:Mexico

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.